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Abstract The microsomal protein cytochrome b5, which
is located in the membrane of the endoplasmic reticulum,
has been shown to modulate many reactions catalyzed by
cytochrome P450 (CYP) enzymes. We investigated the
influence of exposure to the anticancer drug ellipticine and
to two environmental carcinogens, benzo[a]pyrene (BaP)
and 1-phenylazo-2-naphthol (Sudan I), on the expression of
cytochrome b5 in livers of rats, both at the mRNA and
protein levels. We also studied the effects of these com-
pounds on their own metabolism and the formation of
DNA adducts generated by their activation metabo-
lite(s) in vitro. The relative amounts of cytochrome b5
mRNA, measured by real-time polymerase chain reaction
analysis, were induced by the test compounds up to 11.7-
fold in rat livers. Western blotting using antibodies raised
against cytochrome b5 showed that protein expression was
induced by up to sevenfold in livers of treated rats.
Microsomes isolated from livers of exposed rats catalyzed
the oxidation of ellipticine, BaP, and Sudan I and the for-
mation of DNA adducts generated by their reactive
metabolite(s) more effectively than hepatic microsomes
isolated from control rats. All test compounds are known to
induce CYP1A1. This induction is one of the reasons
responsible for increased oxidation of these xenobiotics by
microsomes. However, induction of cytochrome b5 can
also contribute to their enhanced metabolism.
Graphical abstract
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Introduction
Cytochromes b5 are heme proteins which are capable of
accepting and transferring a single electron [1]. One
cytochrome b5 protein, which is located in the membrane
of endoplasmic reticulum (microsomal cytochrome b5), is
involved in fatty acid desaturation, cholesterol and plas-
malogen biosynthesis, as well as in various hydroxylation
reactions catalyzed by cytochrome P450 (CYP) enzymes
[1–7]. The endoplasmic reticulum (microsomal) cyto-
chrome b5 is an integral membrane protein located on the
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outer surface of this cell compartment [3–5, 8] and consists
of two domains, the larger soluble N-terminal heme-bind-
ing core and the smaller hydrophobic C-terminal tail,
which anchors the protein to the membrane. A 15-amino
acid flexible linker connects these two domains providing
the heme domain with sufficient mobility to bind different
redox partners, whereas the protein remains in the mem-
brane. It has been postulated that the linker, consisting of at
least sevenamino acids, is necessary for a productive
interaction with CYP enzymes [9].
Cytochrome b5 can accept an electron from either
NADH:cytochrome b5 reductase or NADPH:cytochrome
P450 (CYP) oxidoreductase (POR) [4, 7, 10] and then
reduced cytochrome b5 transfers this electron to CYPs or
other enzymes (Fig. 1). The role of microsomal cyto-
chrome b5 in the catalytic function of CYPs has not yet
been fully understood. Cytochrome b5 has been shown to
be able to stimulate, inhibit or to have no effect on CYP-
mediated reactions (reviewed in [2, 6, 7, 10]. One
hypothesis trying to explain the influence of cytochrome b5
on CYP reactions suggests a role of cytochrome b5 in the
direct transfer of the second electron to the CYP enzyme,
which is considered to be the rate-limiting step in the
catalytic cycle of the CYP monooxygenase reaction [10].
The electron transfer from reduced cytochrome b5 to CYP
is faster than the input of electrons from POR [7, 11].
Another possible mechanism of the cytochrome b5 action is
the formation of a complex between cytochrome b5 and
CYP, which can receive two electrons from POR in a
single step, one for the reduction of CYP and the other for
the reduction of cytochrome b5 [7]. While CYP without
cytochrome b5 has to undergo two separate interactions
with POR to complete one catalytic cycle, in the presence
of cytochrome b5 only one single interaction complex of
CYP and cytochrome b5 with POR is sufficient; cyto-
chrome b5 provides the second electron to CYP promptly
after oxygen binding. Interaction of cytochrome b5 with
CYP may also induce conformational changes in CYP
proteins leading to the breakdown of the oxygenated
hemoprotein complex with substrates to products. This
hypothesis is based on findings showing that not only the
holoprotein of cytochrome b5, but also its apo-form (devoid
of heme) which is not capable of electron transfer, can
contribute to stimulation effects [6, 7, 10, 12].
It has become clear from these investigations that the
expression levels of cytochrome b5 are crucial for the
efficiency of several CYPs to oxidize some xenobiotics.
This is also true for the oxidation of the anticancer drug
ellipticine and the two environmental carcinogens ben-
zo[a]pyrene (BaP) and 1-phenylazo-2-naphthol (Sudan I).
The oxidation of these xenobiotics by CYP1A1 and/or 3A4
which dictates their biological effects can be strongly
influenced by cytochrome b5 [12–19]. However, the
expression levels of cytochrome b5 as well as the regula-
tion of its expression after xenobiotic exposure remains
largely unknown. Therefore, in this study we investigated
the effect of ellipticine, BaP, and Sudan I on expression of
cytochrome b5 in vivo, both at the transcriptional and
translational levels. Rats, shown to mimic the metabolism
of these compounds in humans [14–25], were used as the
animal model.
Results and discussion
Expression of cytochrome b5 mRNA and protein
levels in rat liver after treatment with ellipticine,
BaP, and Sudan I
We examined the effect of exposure of rats to three
xenobiotics, the anticancer drug ellipticine and the two
environmental carcinogens BaP and Sudan I, on the
expression of cytochrome b5 at the mRNA and protein
levels in the liver, the major organ responsible for
xenobiotic metabolism. We used the real-time poly-
merase chain reaction (RT-PCR) and Western blotting
utilizing antibodies raised against rat cytochrome b5, to
measure the mRNA and protein expression levels,
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Fig. 1 Electron transfer
between components of the
mixed-function oxidase system
(adopted from [4])
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respectively. As shown in Fig. 2, treatment of rats with
ellipticine, BaP, and Sudan I induced expression of
hepatic cytochrome b5 mRNA. The highest induction
was seen in the livers of Sudan I-exposed rats, where
cytochrome b5 mRNA expression increased more than
11-fold; mRNA expression was up to 1.7- and 2.7-fold
higher in rats after treatment with ellipticine and BaP,
respectively (Fig. 2).
In addition to the induction of cytochrome b5 mRNA,
treatment of rats to the test compounds resulted in an up to
sevenfold increase in cytochrome b5 protein levels. This
increase in cytochrome b5 protein levels was similar for all
compounds tested; ellipticine and BaP both caused a five-
fold increase, while Sudan I elevated the level of this
protein by sevenfold (Fig. 3).
The differences in cytochrome b5 mRNA and protein
induction by individual test xenobiotics might be caused by
several phenomena, i.e. a route of administration of test
compounds, a dosage scheme and/or different induction
potency of these xenobiotics. Since ellipticine, BaP, and
Sudan I are strong inducers of CYP1A1, we here used the
route of administration and the dosage schemes that were
analogous to those utilized in studies evaluating the induc-
tion of CYP1A1 mRNA and protein of this enzyme. Under
these conditions, the *34- and *40-fold increases in
expression levels of CYP1A1 protein were due to ellipticine
and BaP, respectively [13, 26], whereas higher potency to
induce this enzyme was caused by Sudan I; an *80-fold
increase in CYP1A1 protein expression levels was found
[27]. These results indicate that the tendency for induction of
CYP1A1 by the compounds examined was similar to that of
cytochrome b5 found in the present work (see Figs. 2 and 3).
The effect of the treatment of rats with ellipticine,
BaP, and Sudan I on hepatic microsomal oxidation
of these compounds and formation of DNA adducts
by their reactive metabolite(s)
Using microsomes isolated from the livers of untreated and
treated rats, we analyzed the oxidation of the test com-
pounds to their metabolites by HPLC. As shown in Fig. 4,
conversion of each of the test compounds to their
metabolites by hepatic microsomes was changed by treat-
ment of rats with the examined xenobiotic, thereby
indicating that the test compound can influence their own
metabolism. The main metabolites formed after the
microsomal oxidation of ellipticine are 9-hydroxy-,
12-hydroxy-, 13-hydroxy-, 7-hydroxyellipticine, and ellip-
ticine N2-oxide (Fig. 4A) which is in line with previous
studies [28]. Microsomal incubation with Sudan I resulted
in the formation of 1-(4-hydroxyphenylazo)-2-naphthol (40-
OH-Sudan I), 1-(phenylazo)-naphthalene-2,6-diol (6-OH-
Sudan I), and 1-(4-hydroxyphenylazo)-naphthalene-2,6-
diol (40,6-diOH-Sudan I) (Fig. 4C) which is in accordance
with studies published previously [20]. Whereas pretreat-
ment of the rats with ellipticine and Sudan I both resulted
in an increase of the metabolites formed by these test
compounds in microsomal incubations, the changes in the
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Fig. 2 Ellipticine-, BaP-, and Sudan I increased expression of
cytochrome b5 mRNA in rat livers. Values represent mean (n = 3);
SDs were less than 10 %. Numbers (F) represent the fold increase
over the control in the amounts of mRNA caused by the treatment of
rats with ellipticine, BaP, and Sudan I. **P\ 0.01; ***P\ 0.001
(Student’s t test), significantly different from controls
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Fig. 3 Induction of cytochrome b5 protein in livers of untreated
(control) rats or rats treated with 40 mg/kg b.w. ellipticine, 125 mg/
kg b.w. BaP, and 60 mg/kg b.w. Sudan I determined by Western
blotting. Insert: Representative immunoblots of hepatic microsomal
cytochrome b5 (cyt b5) stained with antibody against rat cytochrome
b5; imunoblots of glyceraldehyde phosphate dehydrogenase
(GAPDH) that was used as loading control. Control, microsomal
fractions of control (untreated) rats. Values represent mean (n = 3);
SDs were less than 10 %. Numbers (F) represent the fold increase
over the control in the amounts of protein caused by the treatment of
rats with ellipticine, BaP and Sudan I. ***P\ 0.001 (Student’s t test),
significantly different from control
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metabolic profile of BaP were more complex (Fig. 4b). The
main BaP metabolites structurally identified previously in
hepatic microsomal incubation [18] are: BaP-4,5-dihydro-
diol, BaP-7,8-dihydrodiol, BaP-9,10-dihydrodiol, BaP-1,6-
dione, BaP-3,6-dione, BaP-3-ol, and BaP-9-ol. In addition
one metabolite (assigned metabolite Mx) has been found
which structure has not yet been identified. The pattern of
individual BaP metabolites formed by control microsomes
was different from that generated by microsomes isolated
from BaP-pretreated rats. While the formation of BaP-7,8-
dihydrodiol and BaP-3-ol significantly increased in hepatic
microsomal fraction isolated from BaP-pretreated rats, a
significant decrease was found for the metabolites BaP-1,6-
dione, BaP-3,6-dione, BaP-9-ol, and Mx (Fig. 4b). In this
context it is noteworthy that a previous study showed that
the formation of BaP-7,8-dihydrodiol and BaP-3-ol in an
enzyme system containing rat CYP1A1 was increased by
cytochrome b5 [25]. Therefore, the elevated amounts of
these BaP metabolites formed by liver microsomes of BaP-
pretreated rats (compare Fig. 4b) might therefore be
attributable to the BaP-mediated induction of cytochrome
b5.
In further experiments, DNA adduct formation by
ellipticine, BaP, and Sudan I incubated with microsomes
isolated from the livers of untreated and pretreated rats was
compared in vitro. Results with ellipticine and Sudan I
have been previously published [13, 27, 29]. Ellipticine
was activated by these microsomes to form four DNA
adducts (data not shown), two of them were identical to
those formed by 13-hydroxyellipticine and 12-hydroxyel-
lipticine. Additionally, two minor ellipticine-derived DNA
adducts were observed which have been also formed
in vivo [22, 24, 30–32] and in vitro in several enzymatic
systems including CYP enzymes and peroxidases [21, 23,
31–33], but the low adduct levels have prevented their
structural characterization. As shown in Fig. 5 ellipticine-
DNA adduct levels generated by hepatic microsomes iso-
lated from ellipticine-pretreated rats were twofold higher
than those formed by microsomes isolated from untreated
rats [13].
BaP was activated by rat hepatic microsomes to form two
DNA adducts (Fig. 5b). The DNA adduct pattern obtained
by thin-layer chromatrography is shown in the insert of
Fig. 5; BaP-derived DNA adducts 1 and 2 were generated
by incubation of BaP with DNA and microsomes isolated
from livers of both untreated and BaP-pretreated rats. As
discussed previously [18, 34], adduct 1 is probably derived
from 9-hydroxy-BaP-4,5-epoxide with guanine and adduct
2 formed from BaP-7,8-dihydrodiol-9,10-epoxide with
guanine (i.e. 10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-
7,8,9,10-tetrahydro-BaP; dG-N2-BPDE). Pretreatment of
rats with BaP resulted in more than 40- and 15-fold higher
levels of DNA adducts 1 and 2 in microsomal incubations,
respectively (Fig. 5b).
As shown previously [20, 27, 35], hepatic microsomes
isolated from both untreated and Sudan I-pretreated rats
incubated with Sudan I and DNA in vitro generated one
major DNA adduct and two minor adducts (partly over-
lapping with the major adduct). The major adduct was
previously identified by 32P-postlabeling to be the 30,50-
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Fig. 4 Oxidation of ellipticine (a), BaP (b), and Sudan I (c) in
microsomes isolated from livers of untreated (control) rats or rats
pretreated with 40 mg/kg b.w. ellipticine, 125 mg/kg b.w. BaP, and
60 mg/kg b.w. Sudan I. Values represent mean ± SD from three
parallel measurements. *P\ 0.05, **P\ 0.01, ***P\ 0.001 (Stu-
dent’s t test), significantly different from control
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bisphospho-derivative of the 8-(phenylazo)deoxyguanosine
adduct [20, 29]. Microsomes isolated from livers of Sudan
I-pretreated rats were tenfold more efficient to form Sudan
I-derived DNA adducts than those from untreated rats
(compare Fig. 5c).
The increases in oxidation of ellipticine, BaP, and Sudan
I and enhanced DNA adduct formation derived from these
compounds by hepatic microsomes isolated from pre-
treated rats might be caused by several phenomena. As
shown previously, ellipticine, BaP, and Sudan I act as
strong inducers of CYP1A1 in livers of several species
including rats [13, 14, 27, 35] and all test compounds are
substrates of CYP1A1 [13–15, 18, 23–25, 27, 29, 36, 37].
Therefore, induction of CYP1A1 should be one of the
reasons responsible for the elevated oxidation of these
compounds and higher DNA adduct levels. This was also
postulated by us and others in several former studies [13,
14, 27, 35].
However, for ellipticine and BaP, induction of cyto-
chrome b5 also seems to modulate their CYP-mediated
metabolism. The results showing an increase in the oxi-
dation of ellipticine to 7-hydroxyellipticine and
9-hydroxyellipticine by pretreatment of rats with this drug
(Fig. 4a) are consistent with the fact that their formation is
mainly catalyzed by CYP1A1 which is induced by ellip-
ticine treatment [15, 23, 24, 32]. In addition, a twofold
increase in the generation of 12-hydroxy- and 13-hydrox-
yellipticine was observed which, in the absence of
cytochrome b5, are mainly formed by CYP3A (Fig. 4a).
However, under the increased levels of this protein, caused
by its induction in rat liver microsomes, the increase in
formation of these ellipticine metabolites seems to be
mediated mainly by CYP1A1. Namely, a previous study
has shown that cytochrome b5 alters the ellipticine
metabolite profile formed by rat CYP1A1, demonstrating
that the formation of 12-hydroxyellipticine and 13-hy-
droxyellipticine by rat CYP1A1 increased significantly by
cytochrome b5 [15]. The increase in ellipticine oxidation by
hepatic microsomes from the ellipticine-pretreated rats to
12-hydroxy- and 13-hydroxyellipticine also explains the
increase in the levels of ellipticine-derived DNA adducts 1
and 2, because these DNA adducts are generated by
12-hydroxy- (adduct 2) and 13-hydroxyellipticine (adduct
1) [23, 31].
Conclusion
Our study demonstrates that ellipticine, BaP, and Sudan I
are capable of inducing cytochrome b5 in the livers of rats
exposed to these xenobiotics. Cytochrome b5 mRNA
expression was 1.7-, 2.7-, and 11-fold higher by treatment
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Fig. 5 DNA adduct formation by ellipticine (a), BaP (b), and Sudan I
(c) activated with microsomes isolated from livers of untreated
(control) rats or rats pretreated with 40 mg/kg b.w. ellipticine,
125 mg/kg b.w. BaP, and 60 mg/kg b.w. Sudan I. a Adduct data has
been published previously [13]. b Insert Autoradiographic profile of
BaP-DNA adducts formed by hepatic microsomes of BaP-pretreated
rats incubated with BaP and NADPH. The arrows show adduct 1
formed from 9-hydroxy-BaP-4,5-epoxide with deoxyguanosine in
DNA [18] and dG-N2-BPDE adduct (adduct 2). c Adduct data has
been published previously [26]. For all panels, values represent mean
total RAL (relative adduct labeling) ± SD (n = 4; duplicate analyses
of two independent in vitro incubations). **P\ 0.01, ***P\ 0.001
(Student’s t test), significantly different from control
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rats with ellipticine, BaP, and Sudan I, respectively, while
5-, 5- and 7-times higher levels of cytochrome b5 protein
were caused by the test xenobiotics. Since cytochrome b5 is
important for the oxidation of these xenobiotics by
CYP1A1, the induction of both this enzyme and cyto-
chrome b5 by the test compounds exerts a concerted
regulatory control on the CYP1A1-mediated oxidation of
these xenobiotics, thereby modulating their own pharma-
cological and genotoxic potency. However, the mechanism
of cytochrome b5 induction is not yet known. As shown in
several previous studies, all test compounds are ligands of
the aryl hydrocarbon receptor (AhR) [13, 14, 18, 27, 32,
35, 38–42], the receptor whose activation is essential for
the induction of several xenobiotic-metabolizing enzymes.
Consequently, ellipticine, BaP, and Sudan I induce
enzymes that are regulated by the activation of AhR such
as CYP1A1 and NADPH:quinone oxidoreductase (NQO1)
[13, 14, 18, 19, 27, 32, 35]. These findings suggest that the
mechanism of induction of cytochrome b5 might be anal-
ogous to the induction of these enzymes, namely a
mechanism which depends on the activation of AhR.
However, this hypothesis needs to be explored in future
investigations.
Experimental
Ellipticine, BaP, and Sudan I (1-(phenylazo)-2-hydroxy-
naphthalene) were from Sigma Chemical Co (St Louis,
MO, USA).
Animal experiments and isolation of microsomes
All animal experiments were conducted in accordance with
the Regulations for the Care and Use of Laboratory Ani-
mals (311/1997, Ministry of Agriculture, Czech Republic),
which is in compliance with the Declaration of Helsinki.
Male Wistar rats (*125–150 g, AnLab, Czech Republic)
placed in cages in temperature- and humidity-controlled
rooms were acclimatized for 5 days and maintained at
22 C with a 12 h light/dark period. Standardized diet (ST-
1 diet from Velaz, Czech Republic) and water were pro-
vided ad libitum. Rats were treated with ellipticine, BaP,
and Sudan I as follows: (1) Three 5-week-old male Wistar
rats (*125–150 g) were treated i.p. with one dose of
40 mg of ellipticine per kg body weight (b.w.) by
intraperitoneal injection as reported previously [13].
Ellipticine was dissolved in sunflower oil/dimethyl sul-
foxide (1:1 (v/v), 1 cm3). Three control animals received
an equal volume of solvent only [13]. This route of ellip-
ticine administration was used here, because we utilized it
in our former study that investigated ellipticine potency to
induce CYP1A1 [13]. Rats were killed 48 h after the
treatment by cervical dislocation. (2) Three 5-week-old
male Wistar rats (*125–150 g) were treated p.o. by gastric
gavages with a single dose of 150 mg/kg b.w. BaP dis-
solved in 1 cm3 sunflower oil as described previously [42].
Animals in the control group were treated with 1 cm3 of
sunflower oil only. This route of BaP administration was
used, because we utilized it in our former study that
investigated potency of BaP to induce CYP1A1 [26]. Rats
were killed 24 h after the last treatment by cervical dislo-
cation. (3) Three 5-week-old male Wistar rats
(*125–150 g) were injected i.p. with 20 mg/kg b.w.
Sudan I dissolved in 1 cm3 maize oil once a day for 3
consecutive days as reported previously [27]. Animals in
the control group received the same volume of maize oil on
3 days. This route of Sudan I administration and a dosage
scheme were used, because we utilized them in our former
study that investigated potency of Sudan I to induce
CYP1A1 [27]. Rats were killed 24 h after the last treatment
by cervical dislocation. For all treatment groups, livers of
the animals were removed immediately after killing, frozen
in liquid nitrogen, and stored at -80 C until isolation of
microsomal fractions. Pooled microsomes were prepared
from 3 rat livers/group as reported [22, 26, 27]. Microso-
mal fractions were stored at -80 C until analysis. Protein
concentrations in the microsomal fractions were assessed
using the bicinchoninic acid protein assay with bovine
serum albumin as a standard [43].
Content of cytochrome b5 mRNA in rat livers
Total RNA was isolated from another aliquot of frozen
organs using Trizol Reagent (Invitrogen, Carlsbad, CA,
USA) according to the procedure supplied by the manu-
facturer. The quality of isolated RNA was verified by
horizontal agarose gel electrophoresis, RNA quantity was
assessed by UV–Vis spectrophotometry on a Carry 300
spectrophotometer (Varian, Palo Alto, CA, USA). RNA
samples (1 lg) were reversely transcribed into cDNA using
200 U of reverse transcriptase per sample with random
hexamer primers utilizing RevertAidTM First Strand cDNA
Synthesis Kit (MBI Fermentas, Vilnius, Lithuania)
according to the manufacturer’s instructions. RT-PCR was
performed in RotorGene 2000 (Corbett Research, Sydney,
Australia) under the following cycling conditions: incuba-
tion at 50 C for 2 min and initial denaturation at 95 C for
10 min, then 50 cycles of denaturation at 95 C for 15 s
and annealing at 60 C for 1 min, and elongation for 30 s
at 72 C. Gain was set to 7 and fluorescence was acquired
after elongation step. The PCR reaction mixtures
(0.02 cm3) contained 0.009 cm3 cDNA diluted 10-times in
Milli-Q ultrapure water (Biocel A10, Millipore, Billerica,
MA, USA), 0.01 cm3 TaqMan Universal PCR Master Mix
(Applied Biosystems, Foster City, CA, USA), and
M. Stiborova´ et al.
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0.001 cm3 TaqMan Gene Expression Assay Mix (com-
mercially available unlabeled PCR primers and FAMTM
dye-labeled probe for rat cytochrome b5 as the target gene
and b-actin as internal reference standard gene). Each
sample was analyzed in two parallel aliquots. Negative
controls had the same compositions as samples but cDNA
was omitted from the mixture. Data were analyzed by the
program RotorGene v6 (Corbett Research, Sydney, Aus-
tralia) and evaluated by comparative cycle threshold (cT)
method for relative quantitation of gene expression as
described [13].
Cytochrome b5 protein content in microsomes
isolated from rat livers
Microsomes containing 30 lg microsomal proteins were
subjected to electrophoresis on the 15 % polyacrylamide gel
and applied onto a polyvinylidene fluoride (PVDF)membrane
as reported [44]. The membranes were then exposed to
specific rabbit polyclonal anti-cytochrome b5 (1:750,AbCam,
MA, USA) antibodies overnight at 4 C and the antigen–an-
tibody complex was visualized with an alkaline phosphatase-
conjugated goat anti-rabbit IgG antibody (1:1428, Sigma-
Aldrich, USA) and 5-bromo-4-chloro-3-indolylphosphate/
nitrobluetetrazolium as chromogenic substrate. Protein bands
were expressed as arbitrary units (AU)/mg protein as descri-
bed previously [14, 19, 20]. Antibody against glyceraldehyde
phosphate dehydrogenase (GAPDH) (1:750, Millipore, MA,
USA) was used as loading control as recommended by the
antibody producer.
Microsomal incubations to study metabolism
of ellipticine, BaP, and Sudan I
Incubation mixtures used to study ellipticine oxidation
were performed as described previously [21, 24]. Besides
the NADPH-generation system the incubation mixtures
contained 0.5 mg protein of pooled hepatic microsomal
fraction and 0.01 mmol dm-3 ellipticine (dissolved in
0.005 cm3 methanol) in a final volume of 0.5 cm3. The
reaction was initiated by adding ellipticine. In the control
incubation, ellipticine or NADPH-generating system was
omitted from the incubation mixture. After 20 min
(37 C) the reaction was stopped by adding 0.1 cm3 of
2 mol dm-3 NaOH. The oxidation of ellipticine has been
shown to be linear up to 30 min of incubation [23, 28].
After incubation, 0.005 cm3 of 1 mol dm-3 phenacetin in
methanol was added as an internal standard and the
ellipticine metabolites were extracted twice with ethyl
acetate (2 9 1 cm3). Subsequently the solvent was
evaporated to dryness, the residues dissolved in
0.025 cm3 methanol and ellipticine metabolites separated
by HPLC as described [15, 17, 23, 28].
Incubation mixtures used for studying BaP metabolism
by hepatic microsomes contained 100 mmol dm-3 potas-
sium phosphate buffer (pH 7.4), NADPH–generating
system (1 mmol dm-3 NADP?, 10 mmol dm-3 D–glu-
cose-6-phosphate, 1 U/cm3 D-glucose-6-phosphate
dehydrogenase), 0.5 mg protein of pooled hepatic micro-
somal fraction and 0.05 mmol dm-3 BaP (dissolved in
0.005 cm3 DMSO) in a final volume of 0.5 cm3. The
reaction was initiated by adding 0.05 cm3 of the NADPH-
generating system. Control incubations were carried out
either without microsomes, or without NADPH-generating
system, or without BaP. After incubation (37 C, 20 min),
0.005 cm3 1 mmol dm-3 phenacetin in methanol was
added as an internal standard. BaP metabolism by micro-
somes has been shown to be linear up to 30 min of
incubation [18]. BaP metabolites were extracted twice with
ethyl acetate (2 9 1 cm3), solvent evaporated to dryness,
residues dissolved in 0.025 cm3 methanol and BaP
metabolites separated by HPLC as reported [45]. BaP
metabolite peaks were collected and analyzed by NMR
and/or mass spectrometry as described recently [18].
Incubation mixtures used to study Sudan I oxidation had
a final volume of 0.75 cm3, and consisted of
50 mmol dm-3 potassium phosphate buffer (pH 7.4),
1 mmol dm-3 NADPH, 10 mmol dm-3 D-glucose
6-phosphate, 1 unit cm-3 D-glucose 6-phosphate dehy-
drogenase, 10 mmol dm-3 MgCl2, 0.5 mg protein of
pooled hepatic microsomal fraction, and 0.1 mmol dm-3
Sudan I (dissolved in 0.0075 cm3 methanol). After incu-
bation (37 C, 20 min), Sudan I metabolites were extracted
with ethyl acetate (2 9 1 cm3), the extracts evaporated, the
residues dissolved 0.025 cm3 in methanol. Sudan I oxida-
tion by microsomes has been shown to be linear up to
30 min [20]. HPLC analysis was performed as described
previously [20].
Determination of DNA adduct formation
by ellipticine, BaP, and Sudan I in vitro
by 32P-postlabeling
Incubation mixtures used to assess DNA adduct formation
by ellipticine [32], BaP [14], and Sudan I [20, 29] activated
with microsomes isolated from rat liver consisted of
50 mmol dm-3 potassium phosphate buffer (pH 7.4),
1 mmol dm-3 NADPH, 0.5 mg of microsomal proteins,
0.1 mmol dm-3 ellipticine, BaP, or Sudan I (all dissolved
in 0.0075 cm3 dimethyl sulfoxide), and 0.5 mg of calf
thymus DNA in a final volume of 0.75 cm3. The reaction
was initiated by adding 0.1 mmol dm-3 ellipticine, BaP, or
Sudan I. Incubations at 37 C containing ellipticine, BaP,
or Sudan I were carried out for 60, 90, and 60 min,
respectively. Ellipticine-, BaP-, and Sudan I-DNA adduct
formation has been shown to be linear up to 90 min [14,
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16, 20, 29]. Control incubations were carried out either
without microsomes, without NADPH, without DNA, or
without ellipticine, BaP, or Sudan I. After the incubation,
DNA was isolated from the residual water phase by the
phenol/chloroform extraction method. DNA adducts were
analyzed with the nuclease P1 version of the 32P-postla-
beling technique [32]. Resolution of the adducts by thin-
layer chromatography using polyethylenimine-cellulose
plates (Macherey and Nagel, Du¨ren, Germany) was carried
out as follows: (1) Ellipticine-DNA adducts as reported
[13, 32]; (2) BaP-DNA adducts as described [14, 26]; and
(3) Sudan I-DNA adducts as reported [27, 29]. DNA adduct
levels (RAL, relative adduct labeling) were calculated as
described [46].
Statistical analyses
For statistical data analysis we used Student’s t test. All
P values are two-tailed and considered significant at the
0.05 level.
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